Nicha Boonpattrawong

Nicha Boonpattrawong

Auto-generated profile, based on publicly available information

Nicha Boonpattrawong

University of Wisconsin School of Medicine and Public Health, Department of Obstetrics and Gynecology, Madison, WI

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CWChien-Wei Wang
Chien-Wei Wang
SWSimon D. Weaver
Simon D. Weaver
NBNicha Boonpattrawong
Nicha Boonpattrawong
NSNaviya Schuster-Little
Naviya Schuster-Little
Manish PatankarManish Patankar
Manish Patankar
Rebecca WhelanRebecca Whelan
Rebecca Whelan
The biomarker CA125, a peptide epitope located in several tandem repeats of the mucin MUC16, is the gold standard for monitoring regression and recurrence of high-grade serous ovarian cancer in response to therapy. However, the CA125 epitope along with several structural features of the MUC16 molecule are ill defined. One central aspect still unresolved is the number of tandem repeats in MUC16 and how many of these repeats contain the CA125 epitope. Studies from the early 2000s assembled short DNA reads to estimate that MUC16 contained 63 repeats. Here, we conduct Nanopore long-read sequencing of MUC16 transcripts from three primary ovarian tumors and established cell lines (OVCAR3, OVCAR5, and Kuramochi) for a more exhaustive and accurate estimation and sequencing of the MUC16 tandem repeats. The consensus sequence derived from these six sources was confirmed by proteomics validation and agrees with recent additions to the NCBI database. We propose a model of MUC16 containing 19—not 63—tandem repeats. In addition, we predict the structure of the tandem repeat domain using the deep learning algorithm, AlphaFold. The predicted structure displays an SEA domain and unstructured linker region rich in proline, serine, and threonine residues in all 19 tandem repeats. These studies now pave the way for a detailed characterization of the CA125 epitope. Sequencing and modeling of the MUC16 tandem repeats along with their glycoproteomic characterization, currently underway in our laboratories, will help identify novel epitopes in the MUC16 molecule that improve on the sensitivity and clinical utility of the current CA125 assay. Significance: Despite its crucial role in clinical management of ovarian cancer, the exact molecular sequence and structure of the biomarker, CA125, are not defined. Here, we combine long-read sequencing, mass spectrometry, and in silico modeling to provide the foundational dataset for a more complete characterization of the CA125 epitope.

12 September 2025 in bioRxiv
Verified
Preprint
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
AHAlexa R. Heaton
Alexa R. Heaton
SBSamantha K. Burkard
Samantha K. Burkard
ADAurora D’AMato
Aurora D’AMato
NBNicha Boonpattrawong
Nicha Boonpattrawong
LBLisa Barroilhet
Lisa Barroilhet
Melanoma continues to be the deadliest form of skin cancer, emphasizing the need for new therapeutic strategies. Targeting tumor metabolism, particularly oxidative phosphorylation (OXPHOS) has emerged as a promising approach due its role in melanoma tumor survival, metastasis, and treatment resistance. In this study, we investigate the metabolic and antitumor effects of atovaquone, an FDA-approved and safe OXPHOS inhibitor that has not been previously tested in melanoma. We show that atovaquone rapidly and effectively inhibits OXPHOS and impairs glycolysis in melanoma, leading to metabolic reprogramming observed via metabolic imaging and marked depletion in energy (ATP) stores. Atovaquone also induces oxidative stress, evidenced by increased reactive oxygen species levels, DNA damage, and upregulation of antioxidant proteins. Moreover, atovaquone reduced melanoma cell viability and migration in vitro , and slowed tumor growth in vivo . Notably, these effects were observed in both BRAF -wild-type and mutant melanoma models, suggesting its potential as an effective treatment across different subtypes. Our study identifies atovaquone as a metabolic disruptor with antitumor activity against melanoma, supporting further investigation as a repurposed therapeutic strategy.

24 March 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
AHAlexa R. Heaton
Alexa R. Heaton
SBSamantha K. Burkard
Samantha K. Burkard
ADAurora D’AMato
Aurora D’AMato
NBNicha Boonpattrawong
Nicha Boonpattrawong
LBLisa Barroilhet
Lisa Barroilhet

31 January 2024
Verified
Other
Open access
CWChien-Wei Wang
Chien-Wei Wang
SWSimon D. Weaver
Simon D. Weaver
NBNicha Boonpattrawong
Nicha Boonpattrawong
NSNaviya Schuster-Little
Naviya Schuster-Little
Manish PatankarManish Patankar
Manish Patankar
RWRebecca J. Whelan
Rebecca J. Whelan
AlphaFold predicted MUC16 tandem repeat model. The 19 tandem repeat structures were predicted individually and overlaid. All repeats contain a similar structure including two alpha helices, one beta sheet, and a proline/serine/threonine-rich disordered region (this region is not predicted with high confidence and is omitted for clarity).

31 January 2024
Verified
Other
Open access
CWChien-Wei Wang
Chien-Wei Wang
SWSimon D. Weaver
Simon D. Weaver
NBNicha Boonpattrawong
Nicha Boonpattrawong
NSNaviya Schuster-Little
Naviya Schuster-Little
Manish PatankarManish Patankar
Manish Patankar
Rebecca WhelanRebecca Whelan
Rebecca Whelan
AlphaFold predicted MUC16 tandem repeat model. The 19 tandem repeat structures were predicted individually and overlaid. All repeats contain a similar structure including two alpha helices, one beta sheet, and a proline/serine/threonine-rich disordered region (this region is not predicted with high confidence and is omitted for clarity).

31 January 2024
Verified
Other
Open access
PDF file
CWChien-Wei Wang
Chien-Wei Wang
SWSimon D. Weaver
Simon D. Weaver
NBNicha Boonpattrawong
Nicha Boonpattrawong
NSNaviya Schuster-Little
Naviya Schuster-Little
Manish PatankarManish Patankar
Manish Patankar
Rebecca WhelanRebecca Whelan
Rebecca Whelan
AlphaFold predicted models of individual tandem repeats. (A)-(S) Repeats 1-19.